COMPARATIVE OUTCOMES OF LISOCABTAGENE MARALEUCEL VERSUS AN EXTERNAL CONTROL ARM IN THIRD‐LINE OR LATER (3L+) R/R FOLLICULAR LYMPHOMA | Publicación